SCHEMBL2881822

SCHEMBL2881822

CSc1ncc2c(=O)n(C)[nH]c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ALOX5 P09917 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 3/20 0.35
RECQL P46063 1/20 0.35
PPARG P37231 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
NTRK1 P04629 1/20 0.32
FGFR4 P22455 1/20 0.32
TYK2 P29597 4/20 0.31
TDP1 Q9NUW8 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20875578 0.81 PDE4A (0.40) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL20875403 0.80 MEN1 (0.36) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL1812349 0.80 MEN1 (0.36) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL1811493 0.80 ALDH1A1 (0.37) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL25149845 0.80 PIM1 (0.38) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL20875558 0.78 PIM1 (0.36) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL25216988 0.78 MEN1 (0.35) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL20875562 0.78 ALDH1A1 (0.37) MEN1KMT2AKDM4EALDH1A1GLA
SCHEMBL25150559 0.78 JAK2 (0.35) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL25149907 0.76 GAA (0.52) MEN1KMT2AKDM4EGAANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724443-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE Acrivon Therapeutics, Inc. (US) 2026-04-15 EP disclosed
WO-2024254490-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE ACRIVON THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
EP-4416151-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES Padarn Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023125944-A1 COMPOUND CONTAINING HETEROCYCLIC RING 正大天晴药业集团股份有限公司 2023-07-06 WO disclosed
WO-2023064164-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES PADARN THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064164-A1 CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES PADARN THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
US-20200405723-A1 WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2020-12-31 US disclosed
US-9605005-B2 Alkynyl alcohols and methods of use GENENTECH, INC. (US) 2017-03-28 US disclosed
EP-2213673-B1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD KK (JP) 2013-06-05 EP disclosed
EP-2213673-B1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD KK (JP) 2013-06-05 EP disclosed
US-8329711-B2 Pyridone-substituted-dihydropyrazolopyrimidinone derivative MSD K.K. (JP) 2012-12-11 US disclosed
US-8329711-B2 Pyridone-substituted-dihydropyrazolopyrimidinone derivative MSD K.K. (JP) 2012-12-11 US disclosed
US-20100221211-A1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD K.K. (JP) 2010-09-02 US disclosed
US-20100221211-A1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD K.K. (JP) 2010-09-02 US disclosed
EP-2213673-A1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-08-04 EP disclosed
EP-2213673-A1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221211-A1 PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE WEE1, WEE2, CCNE1 MEN1 528/4885KMT2A 1568/4885KDM4E 1850/4885
US-20200405723-A1 WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME WEE1, WEE2, NME1 MEN1 1215/4885KMT2A 701/4885KDM4E 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.